#Boehringer Ingelheim

Boehringer Ingelheim USFDA Approval Boehringer Ingelheim JASCAYD® (nerandomilast) tablets are  approved by the U.S. FDA as an oral treatment for idiopathic pulmonary fibrosis ( IPF ) in adult patients...

Boehringer Ingelheim The following is not for investors but for people who love pets and want them to be healthy and live longer. Those who care about animals should know what’s going on in the highl...

Boehringer Ingelheim Today, Boehringer Ingelheim, a private Company announced that the FIBRONEER™-ILD trial met its primary endpoint, which was the absolute change from baseline in FVC (mL) at week 52...